Samsung Bioepis And C-Bridge Capital Deal Eyes Up ‘Next-Generation’ Biosimilars In China

 
• By Dean Rudge

Partnership, which names Lucentis, Soliris and Herceptin biosimilars as being under its remit, brings together Samsung Bioepis’ “proven agile biologics development platform and C-Bridge’s strong capital resource and China healthcare expertise,” according to the Korean firm.

ChinaWallFlag
Samsung Bioepis continues to make inroads in China. • Source: Shutterstock

More from Biosimilars

More from Products